Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 100

1.

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018.

Brunham LR, Ruel I, Aljenedil S, Rivière JB, Baass A, Tu JV, Mancini GBJ, Raggi P, Gupta M, Couture P, Pearson GJ, Bergeron J, Francis GA, McCrindle BW, Morrison K, St-Pierre J, Henderson M, Hegele RA, Genest J, Goguen J, Gaudet D, Paré G, Romney J, Ransom T, Bernard S, Katz P, Joy TR, Bewick D, Brophy J.

Can J Cardiol. 2018 Dec;34(12):1553-1563. doi: 10.1016/j.cjca.2018.09.005.

PMID:
30527143
2.

Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors.

Genga KR, Lo C, Cirstea MS, Leitao Filho FS, Walley KR, Russell JA, Linder A, Francis GA, Boyd JH.

EBioMedicine. 2018 Nov 22. pii: S2352-3964(18)30536-X. doi: 10.1016/j.ebiom.2018.11.032. [Epub ahead of print]

3.

CETP genetic variant rs1800777 (allele A) is associated with abnormally low HDL-C levels and increased risk of AKI during sepsis.

Genga KR, Trinder M, Kong HJ, Li X, Leung AKK, Shimada T, Walley KR, Russell JA, Francis GA, Brunham LR, Boyd JH.

Sci Rep. 2018 Nov 13;8(1):16764. doi: 10.1038/s41598-018-35261-2.

4.

Nonfasting lipid testing: the new standard for cardiovascular risk assessment.

Darras P, Mattman A, Francis GA.

CMAJ. 2018 Nov 12;190(45):E1317-E1318. doi: 10.1503/cmaj.180804. No abstract available.

PMID:
30420386
5.

Familial hypercholesterolemia in Canada: Initial results from the FH Canada national registry.

Brunham LR, Ruel I, Khoury E, Hegele RA, Couture P, Bergeron J, Baass A, Dufour R, Francis GA, Cermakova L, Mancini GBJ, Brophy JM, Brisson D, Gaudet D, Genest J.

Atherosclerosis. 2018 Oct;277:419-424. doi: 10.1016/j.atherosclerosis.2018.05.040.

PMID:
30270080
6.

Simplified Canadian Definition for Familial Hypercholesterolemia.

Ruel I, Brisson D, Aljenedil S, Awan Z, Baass A, Bélanger A, Bergeron J, Bewick D, Brophy JM, Brunham LR, Couture P, Dufour R, Francis GA, Frohlich J, Gagné C, Gaudet D, Grégoire JC, Gupta M, Hegele RA, Mancini GBJ, McCrindle BW, Pang J, Raggi P, Tu JV, Watts GF, Genest J.

Can J Cardiol. 2018 Sep;34(9):1210-1214. doi: 10.1016/j.cjca.2018.05.015. Epub 2018 May 19.

7.

Attainment of Recommended Lipid Targets in Patients With Familial Hypercholesterolemia: Real-World Experience With PCSK9 Inhibitors.

Razek O, Cermakova L, Armani H, Lee T, Francis GA, Mancini GBJ, Frohlich J, Brunham LR.

Can J Cardiol. 2018 Aug;34(8):1004-1009. doi: 10.1016/j.cjca.2018.04.014. Epub 2018 Apr 20.

PMID:
30056842
8.

The design and rationale of SAVE BC: The Study to Avoid CardioVascular Events in British Columbia.

Brunham LR, Lynch K, English A, Sutherland R, Weng J, Cho R, Wong GC, Anis AH, Francis GA, Khan NA, McManus B, Wood D, Walley KR, Leipsic J, Humphries KH, Hoens A, Krahn AD, John Mancini GB, Pimstone S.

Clin Cardiol. 2018 Jul;41(7):888-895. doi: 10.1002/clc.22959. Epub 2018 Jun 11.

9.

LAL (Lysosomal Acid Lipase) Promotes Reverse Cholesterol Transport In Vitro and In Vivo.

Bowden KL, Dubland JA, Chan T, Xu YH, Grabowski GA, Du H, Francis GA.

Arterioscler Thromb Vasc Biol. 2018 May;38(5):1191-1201. doi: 10.1161/ATVBAHA.117.310507. Epub 2018 Mar 29.

PMID:
29599133
10.

Response by Kusters et al to Letter Regarding Article, "Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)".

Kusters DM, Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Raichlen J, Martin PD, Stein EA, Kastelein JJP, Hutten BA.

Circulation. 2018 Feb 6;137(6):641-642. doi: 10.1161/CIRCULATIONAHA.117.031676. No abstract available.

PMID:
29431667
11.

Smooth muscle cell fate and plasticity in atherosclerosis.

Allahverdian S, Chaabane C, Boukais K, Francis GA, Bochaton-Piallat ML.

Cardiovasc Res. 2018 Mar 15;114(4):540-550. doi: 10.1093/cvr/cvy022.

PMID:
29385543
12.

Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or Ezetimibe.

Ruel I, Aljenedil S, Sadri I, de Varennes É, Hegele RA, Couture P, Bergeron J, Wanneh E, Baass A, Dufour R, Gaudet D, Brisson D, Brunham LR, Francis GA, Cermakova L, Brophy JM, Ryomoto A, Mancini GBJ, Genest J.

Clin Chem. 2018 Feb;64(2):355-362. doi: 10.1373/clinchem.2017.279422. Epub 2017 Oct 16.

PMID:
29038147
13.

Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label).

Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Kusters DM, Raichlen JS, Martin PD, Stein EA, Kastelein JJP, Hutten BA.

Circulation. 2017 Jul 25;136(4):359-366. doi: 10.1161/CIRCULATIONAHA.116.025158. Epub 2017 Jun 7.

PMID:
28592434
14.

Contemporary Trends in the Management and Outcomes of Patients With Familial Hypercholesterolemia in Canada: A Prospective Observational Study.

Brunham LR, Cermakova L, Lee T, Priecelova I, Alloul K, de Chantal M, Francis GA, Frohlich J.

Can J Cardiol. 2017 Mar;33(3):385-392. doi: 10.1016/j.cjca.2016.08.016. Epub 2016 Sep 3.

15.

2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.

Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, Francis GA, Genest J Jr, Grover S, Gupta M, Hegele RA, Lau DC, Leiter LA, Lonn E, Mancini GB, McPherson R, Ngui D, Poirier P, Sievenpiper JL, Stone JA, Thanassoulis G, Ward R.

Can J Cardiol. 2016 Nov;32(11):1263-1282. doi: 10.1016/j.cjca.2016.07.510. Epub 2016 Jul 25. Review.

PMID:
27712954
16.

So Much Cholesterol: the unrecognized importance of smooth muscle cells in atherosclerotic foam cell formation.

Dubland JA, Francis GA.

Curr Opin Lipidol. 2016 Apr;27(2):155-61. doi: 10.1097/MOL.0000000000000279. Review.

PMID:
26836481
17.

Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study.

Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagné C, Gaudet D, Morrison KM, Wiegman A, Turner T, Kusters DM, Miller E, Raichlen JS, Wissmar J, Martin PD, Stein EA, Kastelein JJP.

J Clin Lipidol. 2015 Nov-Dec;9(6):741-750. doi: 10.1016/j.jacl.2015.07.011. Epub 2015 Aug 1.

PMID:
26687694
18.

Colesevelam as an Add-On Treatment for Control of Dyslipidemia and Hyperglycemia in Type 2 Diabetes.

Sandhu S, Moosavi M, Golmohammadi K, Francis GA.

Can J Diabetes. 2016 Apr;40(2):112-4. doi: 10.1016/j.jcjd.2015.07.008. Epub 2015 Nov 12. Review. No abstract available.

PMID:
26584788
19.

Targeted next-generation sequencing to diagnose disorders of HDL cholesterol.

Sadananda SN, Foo JN, Toh MT, Cermakova L, Trigueros-Motos L, Chan T, Liany H, Collins JA, Gerami S, Singaraja RR, Hayden MR, Francis GA, Frohlich J, Khor CC, Brunham LR.

J Lipid Res. 2015 Oct;56(10):1993-2001. doi: 10.1194/jlr.P058891. Epub 2015 Aug 8.

20.

The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance.

Walley KR, Francis GA, Opal SM, Stein EA, Russell JA, Boyd JH.

Am J Respir Crit Care Med. 2015 Dec 1;192(11):1275-86. doi: 10.1164/rccm.201505-0876CI.

PMID:
26252194

Supplemental Content

Loading ...
Support Center